64Cu-Labeled F(ab’)2 Fragments of Daratumumab for Early Visualization of CD38-positive Lymphoma

Kang Liu,Dawei Jiang,Weijun Wei,Dalong Ni,Carolina A. Ferreira,Jonathan W. Engle,Rongfu Wang,Weibo Cai

2019-01-01

Abstract:350 Purpose: CD38 showed strongly over-expression in several kinds of lymphoma, especially for multiple myeloma (MM). Daratumumab is a FDA-approved CD38 specific monoclonal human antibody, which could be used for immunoPET imaging after radiolabeling. However, the intact antibody usually has a long blood circulation and late uptake peak in target. Therefore, this study used the F(ab’)2 fragments of daratumumab to visualize CD38 in a CD38-positive lymphoma model. Methods: F(ab’)2 fragments of daratumumab were prepared using IdeS enzyme and purified with Protein A beads. They were further tested by HPLC and gel electrophoresis. After conjugated with p-SCN-Bn-NOTA (NOTA), the fragments were radiolabeled with 64Cu (t1/2 = 12.7 h). F(ab’)2 fragments of human non-specific IgG and the intact antibody daratumumab were used as controls and prepared using the same methods. In vitro, fluorescein dye conjugated daratumumab-F(ab’)2 was used to evaluate the cellular uptake. CD38-positive Ramos cells were implanted subcutaneously to build a lymphoma murine model. Serial small animal PET imaging was performed after injection of 64Cu labeled F(ab’)2-daratumumab, 64Cu labeled F(ab’)2-IgG or intact daratumumab. PET data were analyzed by drawing ROI. Biodistribution study and histological staining were performed at the end of time point. Results: HPLC and SDS-PAGE results showed that the molecular weight of F(ab’)2 fragments was about 110 kDa, suggesting a successful digestion. Fluorescein dye conjugated F(ab’)2-daratumumab bound with cell membrane, observed by microscopy. After conjugated with NOTA, the F(ab’)2 fragments or intact antibody were labeled with 64Cu (labeling yield > 90%). PET imaging showed 64Cu-NOTA-F(ab’)2-daratumumab had a rapid and high tumor uptake as early as 4 h post-injection (8.2 ± 0.9 %ID/g) and reached the peak at 12 h (9.5 ± 0.7 %ID/g) (n = 4). In the comparison, 64Cu-NOTA -F(ab’)2-IgG demonstrated a near-background tumor uptake in Ramos model (no more than 2% at any time point). Both of labeled F(ab’)2 fragments showed the highest uptake in kidneys. Even 64Cu labeled intact antibody showed an increasing tumor uptake (up to 8.3 ± 1.4 %ID/g at 48 h), uptake in the blood pool was still high (6.9 ± 0.8 %ID/g at 48 h), as well as other blood-rich organs. The tumor-to-background ratios of 64Cu-NOTA -F(ab’)2-daratumumab were significantly higher than those of daratumumab after 4 h post injection (P<0.05). 64Cu-NOTA -F(ab’)2-daratumumab showed the highest tumor-to-blood ratio at 18.9 ± 4.6 and tumor-to-muscle ratio at 40.4 ± 1.6 at 48 h, while the ratios of intact antibody were 1.2 ± 0.3 (blood) and 13.1 ± 6.0 (muscle), respectively. Biodistribution results at 48 h post-injection verified the PET imaging results. Finally, immunofluorescent staining confirmed the Ramos tumor showed strong expression of CD38. Conclusions: 64Cu labeled F(ab’)2-daratumumab showed an early and high tumor uptake in CD38-positive lymphoma, along with low background, thus it provides a potential PET imaging agent for better usage in clinic in the future.